5305-45-3

Basic information

• Product Name: 4,6-dichloropyrimidine-5-carbonitrile
• Synonyms: 4,6-dichloropyrimidine-5-carbonitrile;4-aMino-2,6-dichloropyriMidine-5-carbonitrile;4,6-Dichloro-5-cyanopyriM...;5-PyriMidinecarbonitrile, 4,6-dichloro-;4,6-Dichloropyrimidine-5-carbonitrile 4,6-Dichloro-5-cyanopyrimidine;4,6-Dichloro-5-pyrimidinecarbonitrile
• CAS NO: 5305-45-3
• Molecular Formula: C₅HCl₂N₃
• Molecular Weight: 173.99
• EINECS: 200-110-4
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 5305-45-3.mol
• Article Data: 14

Chemical Properties

• Melting Point: 145 °C
• Boiling Point: 335.2°C at 760 mmHg
• Flash Point: 156.5°C
• Appearance: /
• Density: 1.60
• Vapor Pressure: 0.000122mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -7.00±0.26(Predicted)
• CAS DataBase Reference: 4,6-dichloropyrimidine-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloropyrimidine-5-carbonitrile(5305-45-3)
• EPA Substance Registry System: 4,6-dichloropyrimidine-5-carbonitrile(5305-45-3)

Safety Data

• Hazardous Substances Data: 5305-45-3(Hazardous Substances Data)

Usage

Uses

4,6-dichloropyrimidine-5-carbonitrile can be used as organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and chemical production process.

Synthesis

4,6-Dichloro-5-pyrimidinecarbaldehyde oxime (8 g) was dissolved in CHCl3 (40 mL) and treated with SOCl2 (6 mL) for 2 h at rt. The solvent was removed and the residue was dissolved in DCM (5 mL). The resulting solid was filtered and washed with DCM (5 mL). The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography using DCM-hexane (3:1) to give 4,6-dichloro-5-pyrimidinecarbonitrile. White solid.

InChI:InChI=1/C5HCl2N3/c6-4-3(1-8)5(7)10-2-9-4/h2H

Upstream product

• 15263-75-9 N-((4,6-dihydroxypyrimidin-5-yl)methylene)-N-methylmethylammonium chloride salt 
• 5305-40-8 2,6-dichloro-pyrimidine carbaldehyde 
• 5305-43-1 C₅H₂ClN₃O 
• 1277179-40-4 4, 6-dichloropyrimidine-5-carbaldehyde oxime 
• 911461-47-7 iminohydroxy intermediate 
• 7660-48-2 4,6-dichloropyrimidine-5-carbaldehyde oxime 

Downstream Products

• 425394-86-1 4-chloro-5-cyano-6-methoxypyrimidine 
• 914308-84-2 4-chloro-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbonitrile 
• 944342-92-1 4-(4-benzyloxy-3-chloro-phenylamino)-6-chloro-pyrimidine-5-carbonitrile 
• 733748-89-5 4-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-6-(4-methanesulfonyl-phenoxy)-pyrimidine-5-carbonitrile 
• 1338484-57-3 methyl 2-((1S)-1-((6-amino-5-cyano-4-pyrimidinyl)amino)ethyl)-3-phenylimidazo[1,2-a]pyridine-5-carboxylate 
• 1312606-04-4 4-Amino-6-((1-(2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1312605-97-2 4-amino-6-((1-(7-fluoro-2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1312605-53-0 4-amino-6-((2-(3-fluorophenyl)-1,5-naphthyridin-3-yl)methoxy)-5-pyrimidinecarbonitrile 
• 60025-09-4 4-amino-6-chloropyrimidine-5-carbonitrile 
• 902746-39-8 C₁₆H₁₉N₅OS 
• 902747-17-5 C₁₈H₁₄FN₅O₂S 
• 902747-12-0 C₁₆H₁₂BrN₅OS 
• 902747-21-1 C₁₈H₁₄FN₅O₂S 
• 902746-41-2 C₁₇H₁₉N₅OS 

Relevant articles and documents

An Alternative Scalable Process for the Synthesis of 4,6-Dichloropyrimidine-5-carbonitrile

A robust, safe, and scalable process for the synthesis of 4,6-dichloropyrimidine-5-carbonitrile is described. All of the intermediates in the process are storable under normal conditions. Significant process safety evaluation was undertaken in this route, and the highlights of these studies are presented. This scalable and safe synthetic strategy can be applied for multikilogram-scale production.

QUINOLINE DERIVATIVES AS PIK3 INHIBITORS

Substituted bicyclic heteroaryls having the general formula (I) and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pl 108 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML), Myelodysplastic syndrome (MDS), myeio-proiiferative diseases (MPD), Chronic Myeloid Leukemia (CML), T-cell Acute Lymphoblastic leukaemia (T-ALL), B-cell Acute Lymphoblastic leukaemia (B-ALL), Non Hodgkins Lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.

Synthesis of Janus type nucleoside analogues and their preliminary bioactivity

Novel Janus type nucleoside analogues 1a and 1b were synthesized in seven steps from 2-amino-4,6-dihydroxypyrimidine and 4,6-dihydroxypyrimidine. The base moiety of 1a has one face with a Watson-Crick donor-donor-acceptor (DDA) H-bond array of guanine and